Sino Biopharmaceutical Limited

Informe acción SEHK:1177

Capitalización de mercado: HK$50.2b

Sino Biopharmaceutical Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Los beneficios de Sino Biopharmaceutical han disminuido a una tasa media anual de -9.7%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 5.9% anualmente. Los ingresos han ido creciendo a una tasa media de 5.3% al año. La rentabilidad financiera de Sino Biopharmaceutical es de 12.1%, y sus márgenes netos son de 7.1%.

Información clave

-9.7%

Tasa de crecimiento de los beneficios

-9.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals 5.6%
Tasa de crecimiento de los ingresos5.3%
Rentabilidad financiera12.1%
Margen neto7.1%
Última actualización de beneficios31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21
Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20
Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Dec 18
Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon

Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Dec 02
Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?

Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

Nov 17
Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate

We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Aug 30
We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

May 26
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Apr 20
Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet

Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Feb 09
Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Nov 11
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Oct 24
Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Jul 08
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?

Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

Apr 28
Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?

An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued

Jan 22
An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued

Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet

Dec 03
Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Oct 19
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?

Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02

Sep 03
Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02

These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well

Aug 27
These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well

Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 38% Undervaluation?

Jul 14
Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 38% Undervaluation?

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Sino Biopharmaceutical. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SEHK:1177 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 2326,1991,84711,0670
30 Jun 2328,8641,88112,0740
31 Mar 2328,8222,21212,3190
31 Dec 2228,7802,54412,5640
30 Sep 2228,2415,29612,7050
30 Jun 2227,7018,04912,8460
31 Mar 2227,21513,65512,6690
31 Dec 2126,86114,60812,7040
30 Sep 2126,12912,46512,7180
30 Jun 2125,35310,01112,7540
31 Mar 2124,6683,80912,1980
31 Dec 2023,6472,77111,6290
30 Sep 2023,0392,30211,2540
30 Jun 2024,3542,55811,4900
31 Mar 2024,2482,78111,7620
31 Dec 1924,2342,76211,7970
30 Sep 1924,4799,10112,5440
30 Jun 1923,6919,12511,8010
31 Mar 1922,4449,13211,0360
31 Dec 1820,8899,04610,2680
30 Sep 1819,1032,5678,7990
30 Jun 1817,0622,4367,9210
31 Mar 1815,6092,3637,3340
31 Dec 1714,8192,1716,9050
30 Sep 1714,4912,1156,6800
30 Jun 1714,2581,8626,6680
31 Mar 1713,8991,7896,5250
31 Dec 1613,5431,6376,4930
30 Sep 1613,2711,6746,3440
30 Jun 1612,8581,6046,2720
31 Mar 1612,5071,5756,0840
31 Dec 1512,1891,4905,9740
30 Sep 1512,0301,4325,9940
30 Jun 1511,1241,4475,4830
31 Mar 1510,5521,2635,2520
31 Dec 149,9001,2104,9330
30 Sep 149,2051,0744,4570
30 Jun 148,8769514,3660
31 Mar 148,4348864,2870
31 Dec 137,7318093,9450
30 Sep 138,0698684,1740
30 Jun 136,9028153,6210

Ingresos de calidad: 1177 tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(7.1%) de 1177 son inferiores a los del año pasado (8.8%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 1177 han disminuido en un 9.7% al año en los últimos 5 años.

Acelerando crecimiento: 1177 ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: 1177 tuvo un crecimiento negativo de los beneficios (-27.4%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (1.3%).


Rentabilidad financiera

Alta ROE: La rentabilidad financiera de 1177 (12.1%) se considera baja.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target